Table 1.
Immunohistochemical quantification of inflammatory cells
| Detection system | DAB Zytomed HRP kit | |||||
|---|---|---|---|---|---|---|
| Measured parameter | Positive cells per HPF (AM ± SD) | |||||
| Antibody | CD3 | CD20 | CD68 | FOXP3 | Mast cell tryptase+ | |
| Company | Dako | Dako | Dako | Zytomed | Leica | |
| Group | Dilution | 1:200 | 1:50 | 1:100 | 1:100 | 1:50 |
| UIP | Peribronchial | 66.4 ± 17.3*** | 82.3 ± 25.7*** | 12.4 ± 4.6*** | 6.9 ± 4.0* | 0.0 ± 0.0 |
| Fibroblastic foci | 2.3 ± 2.8 | 1.1 ± 1.8 | 13.3 ± 4.6*** | 0.5 ± 1.1 | 0.0 ± 0.0 | |
| Remodelled interstitium | 12.0 ± 6.2*** | 10.9 ± 4.2*** | 57.3 ± 10.8*** | 0.8 ± 1.4 | 3.0 ± 0.8*** | |
| NSIP | Peribronchial | 54.5 ± 12.7*** | 54.5 ± 12.7*** | 9.3 ± 2.6*** | 8.9 ± 6.1* | 0.1 ± 3.0 |
| Remodelled interstitium | 11.0 ± 3.9*** | 5.3 ± 3.0** | 11.7 ± 4.6*** | 4.9 ± 4.0** | 2.1 ± 1.2*** | |
| OP | Peribronchial | 62.4 ± 21.7*** | 77.1 ± 10.1*** | 10.8 ± 3.4*** | 8.9 ± 6.3* | 0.0 ± 0.0 |
| OP lesion | 1.9 ± 3.4 | 4.1 ± 5.2 | 12.6 ± 5.1*** | 0.8 ± 1.4 | 1.0 ± 0.9 | |
| AFE | Peribronchial | 99.6 ± 16.5*** | 118.4 ± 8.2*** | 37.1 ± 6.4*** | 12.9 ± 7.2 | 0.0 ± 0.0 |
| AFE lesion | 40.8 ± 16.2*** | 50.3 ± 17*** | 42.3 ± 19.6*** | 6.4 ± 6.7* | 0.8 ± 0.9 | |
| Controls | Peribronchial | 14.9 ± 7.0 | 24.5 ± 9.0 | 4.5 ± 1.9 | 3.9 ± 3.7 | 0.0 ± 0.0 |
| Interstitium | 3.9 ± 2.1 | 2.3 ± 1.5 | 4.1 ± 2.4 | 1.4 ± 2.0 | 0.4 ± 0.7 | |
A Student's t‐test of absolute cell counts was performed on all diseased tissues against the respective control tissue (‘AFE lesion’, ‘OP lesion’ and ‘fibroblastic foci’ were compared against the interstitium of controls). Further pairwise comparisons are included in supplementary material, Figure S1.
*
p < 0.05; significant difference against control.
**
p < 0.01; significant difference against control.
***
p < 0.001; significant difference against control.